WHO Addresses Vaccine Anaphylaxis, Drug Resistance, H1N1 Mutations
The World Health Organization has addressed several 2009 H1N1 reports that have received a lot of press attention over the past week, including post-vaccination anaphylaxis, clusters of oseltamivir resistance, and an H1N1 mutation.
Among the comments from Dr. Keiji Fukuda, the organization’s special adviser on pandemic influenza:
- Post-vaccination anaphylaxis in six Canadians is under investigation; all patients recovered without hospitalization, and unused vaccine doses from the lot in question are on hold.
- Two clusters of oseltamivir resistance, found in the U.S. and U.K., were limited to severely immunocompromised patients (e.g., HIV, hematologic cancer) and likely do not signal a change in the virus.
- An H1N1 mutation, observed in the U.S., Norway, China, and other countries, is being examined to determine whether it causes more severe disease and whether it’s becoming more prevalent. Dr. Fukuda emphasized that “mutations in and of themselves are not necessarily important.”